Form 4: Apogee Therapeutics CEO Michael Henderson Sells Shares Under 10b5-1 Trading Plan

Apogee Therapeutics CEO Michael Henderson sold a portion of his common stock holdings on August 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Henderson, CEO of Apogee Therapeutics, sold shares of common stock on August 7, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 25, 2023.
• A total of 40,000 shares were sold in multiple transactions at varying prices.
• The weighted average sale prices were $40.40, $41.52 and $42.17.
• Following the transactions, Henderson directly owns 1,434,487 shares of Apogee Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sale was pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a negative outlook, but it's a transaction investors should be aware of.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, regardless of the reason for the sale.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sale, although the existence of a 10b5-1 plan should mitigate concerns.

Key Dates